PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1928945
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1928945
The Global Synthetic Biology Market was valued at USD 25.6 billion in 2025 and is estimated to grow at a CAGR of 17.5% to reach USD 128.1 billion by 2035.

Synthetic biology is revolutionizing the way we engineer biological systems by integrating engineering principles with biology to design novel biological components, devices, and systems. The field has evolved from simple genetic engineering to advanced platforms that enable precise programming of cellular functions. This transformation is driven by breakthroughs in DNA synthesis and sequencing, computational biology, and deeper insights into biological design. The market spans enabling products such as oligonucleotides, enzymes, and chassis organisms; core products including synthetic genes, cells, and DNA libraries; and enabled products covering pharmaceuticals, industrial chemicals, biofuels, and biomaterials. Cutting-edge genome editing technologies like CRISPR-Cas9 have accelerated the adoption of synthetic biology across therapeutics, agriculture, and industrial sectors, while also offering sustainable alternatives to traditional resource-intensive processes.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $25.6 Billion |
| Forecast Value | $128.1 Billion |
| CAGR | 17.5% |
The enabling products segment reached USD 11.5 billion in 2025 and is expected to grow at a CAGR of 16.5% through 2035. This category includes essential tools and reagents required for synthetic biology R&D, such as oligonucleotides, enzymes like polymerases and ligases, cloning kits, chassis organisms like bacterial, yeast, and mammalian cell lines, and software platforms for design and simulation. Its dominance reflects the foundational role these products play in supporting all synthetic biology initiatives.
The pharmaceuticals and therapeutics segment reached USD 10.2 billion in 2025 and is projected to grow at a CAGR of 14.5% through 2035. This segment encompasses cell and gene therapies, mRNA vaccines, engineered biologics, and biosynthetic small molecules. Commercial and clinical validation has been achieved for multiple products, positioning pharmaceuticals and therapeutics as the most commercially advanced area of synthetic biology.
U.S. Synthetic Biology Market was valued at USD 8.6 billion in 2025 and is expected to reach USD 43.1 billion by 2035. Strong government backing supports research and development, including USD 161 million allocated by various agencies in 2020 for biomanufacturing and bioenergy, alongside USD 178 million from the Department of Energy in 2022 aimed at developing sustainable alternatives to petroleum-based products.
Leading companies in the Global Synthetic Biology Market include Novozymes, GenScript, Thermo Fisher Scientific, Ginkgo Bioworks, Twist Bioscience, Integrated DNA Technologies, ATUM, Blue Heron, Amyris, BASF, Biomax Informatics, Pareto Biotechnologies, Gevo Inc., Royal DSM, Bristol-Myers Squibb, Genomatica, Synthetic Genomics, Codexis, Butamax Scarab Genomics, MorphoSys, Evolva, and Igenbio. Key strategies adopted by synthetic biology companies to strengthen their market presence include investing heavily in research and development to create advanced, high-precision solutions, expanding product portfolios through acquisitions and strategic partnerships, and forming collaborations with academic and industrial research institutions. Companies are also focusing on scaling manufacturing capabilities, integrating AI and computational tools for better biological design, and entering emerging geographic markets to expand their global footprint.